UPDATE: Ascendiant Capital Starts Atossa Genetics (ATOS) at Buy

(updating comment)

Ascendiant Capital analyst Edward Woo initiates coverage on Atossa Genetics (NASDAQ: ATOS) with a Buy rating and a price target of $7.00.

The analyst comments "Current valuation attractive: We calculate a 12-month price target for shares of Atossa to be $7.00 based on a NPV analysis, representing significant upside from the current share price. We believe this valuation appropriately balances out the company’s high risks with the company’s high growth prospects and large upside opportunities."

For an analyst ratings summary and ratings history on Atossa Genetics click here. For more ratings news on Atossa Genetics click here.

Shares of Atossa Genetics closed at $2.25 yesterday.

You May Also Be Interested In

• Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
• JPMorgan Upgrades Akamai Technologies (AKAM) to Neutral 'on Account of Confidence in Revenue Reacceleration'
• Needham Reiterates Hold Rating on CoreWeave (CRWV)